Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4388 - Antiviral Prophylaxis Cannot Reduce the Risk of Hepatitis B Reactivation During Chemotherapy for non HCC Solid Tumor Patients with Lower HBV DNA Titer:A Retrospective Cohort Study.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

qiong qin

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

Q. qin1, A. Zhou2, L. Yang2, D. Zhong3

Author affiliations

  • 1 Medical Oncology, Tianjin Medical University General Hospital, 300052 - Tianjin/CN
  • 2 Department Of Medical Oncology, National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 3 Medical Respiratory, Tianjin Medical University General Hospital, Tianjin/CN
More

Resources

Abstract 4388

Background

The high-risk factors related to HBV reactivation during chemotherapy include lymphoma, hematopoietic stem cell transplantation (HSCT), treatment regimen containing rituximab, a high HBV viral load before chemotherapy and baseline prechemotherapy HBeAg positivity. However, the role of antiviral prophylaxis in preventing HBV reactivation in patients with non- hepatocellular carcinoma (HCC) solid tumor and lower HBV DNA titer is unclear.

Methods

Between January 2011 and March 2018, all HBsAg seropositive patients with solid tumor receiving cytotoxic chemotherapy were retrospectively evaluated. The titer of HBV DNA and liver function were routinely examined before chemotherapy. The patients whose titer of HBV DNA was under 100 IU/ml were eligible. HBV reactivation, hepatotoxicity and disruption of chemotherapy attributed to HBV reactivation were compared according to antiviral prophylaxis.

Results

Of 170 consecutive patients eligible for, 102 were treated without antiviral prophylaxis and 68 received antiviral prophylaxis. 55 patients were treated with entecavir, 7 for lamivudine and 6 for adefovir. The two groups were comparable in most clinical baseline characteristic including gender distribution, age, tumor types, tumor stage, the use of prednisone and/or anthracyclines. There was no significant difference between the two groups (P = 0.587). Patients without antiviral prophylaxis had a similar prevalence of HBV reactivation (6.8% vs 4.4%, P = 0.741) and severe hepatitis attributable to reactivation (4.9% vs 4.4%, P = 0.882). No patients died ultimately from fulminant hepatitis. Furthermore, no significant difference in disruption of chemotherapy was noted between patients with or without antiviral prophylaxis (3.9% vs 4.4%, P = 0.875).

Conclusions

For patients with non-HCC solid tumors and the titer of HBV DNA less than 100IU/ml before chemotherapy, antiviral prophylaxis failed to further reduce the reactivation of HBV. For such patients, regular monitoring of HBV viral load maybe more reasonable and cost-effective optimal choice.

Clinical trial identification

Legal entity responsible for the study

Clinical research Ethics Comittee of Tianjin Medical University General Hospital and National Cancer Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.